Elys Game Technology, Corp.

Elys Game Technology, Corp. (NASDAQ: ELYS) is a growing, technologically advanced Sports Betting and i-Gaming full-service provider in the regulated B2B and B2C markets. It focuses on delivering outcomes for casino and leisure gaming operators in Europe, North America, and worldwide through retail and digital solutions.

Key Highlights

• The company reported a 37.25% increase in revenues to USD 33.88 million during 9MFY21 (ended September 30, 2021) compared to USD 24.68 million during 9MFY20.
• Due to increasing operational expenditures such as personnel costs, professional fees, and IT related costs, ELYS witnessed an increase in operating losses to USD 6.43 million during 9MFY21 vs. USD 1.51 million during 9MFY20.
• The company is operating at a ROE and net margins of -14.3% and -43.8% in Q3FY21.
• On November 11, 2021, ELYS and Atlantic City's Ocean Casino Resort announced a collaboration that would begin on March 1, 2022. USBookmaking, a subsidiary of ELYS, will supply Ocean's trade management services and eventual retail solution, subject to regulatory approval from New Jersey's gambling regulators.
• The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 27.72.
• Stock is leaning towards the lower band of the 52-week range of USD 1.40 to USD 8.28.
• ELYS stock price has declined 32.37% and 45.61% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the uncertain outlook, high operating losses, doubtful positive bottomline results in the near future, and technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 3.28, down 1.80% as of November 23, 2021, at 2:20 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

BIOLASE, Inc.

BIOLASE, Inc. (NASDAQ: BIOL) is a major manufacturer of innovative dental laser equipment. The company creates, manufactures, promotes, and distributes laser systems that assist dental professionals and their patients.

Key Highlights

• The company reported a 87.80% increase in revenues to USD 26.78 million during 9MFY21 (ended September 30, 2021) compared to USD 14.26 million during 9MFY20.
• Due to increasing operational expenditures and loss on patent litigation settlement, BIOL witnessed an increase in net losses to USD 10.88 million during 9MFY21 from USD 10.69 million during 9MFY20.
• The company is operating at a ROE and net margins of -10.3% and -34.4% in Q3FY21.
• On November 17, 2021, BIOL asks stockholders to vote in favour of a reverse stock split adjustment (without reducing the authorised number of shares of common stock).
• The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 21.61.
• Stock is leaning towards the lower band of the 52-week range of USD 0.27 to USD 1.51.
• BIOL stock price has declined 37.47% and 56.52% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the uncertain outlook, doubtful positive bottomline results in the near future, and technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4211, down 4.53% as of November 23, 2021, at 2:27 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.